Abstract | PURPOSE: MATERIALS AND METHODS: A single-center retrospective study of 302 patients (258 men; 85.4%) with HCC treated during a 20-month period was conducted. The mean patient age was 66 years ± 10; 142 (47%) had Barcelona Clinic Liver Cancer stage A disease and 134 had (44.4%) stage B disease; 174 (57.6%) had a single HCC tumor, 65 (21.5%) had 2, and 62 (20.9%) had 3 or more. Mean index tumor size was 36.6 mm ± 24.8. One-month follow-up computed tomography (CT) response per modified Response Evaluation Criteria In Solid Tumors and clinical and biochemical safety were analyzed. Progression-free and overall survival were calculated by Kaplan-Meier method. RESULTS: Median follow-up time was 11.9 months (95% confidence interval, 11.0-13.0 mo). One-month follow-up CT revealed complete response in 179 patients (63.2%), partial response in 63 (22.3%), stable disease in 16 (5.7%), and progressive disease in 25 (8.8%). The most frequent complications were postembolization syndrome in 18 patients (6%), liver abscess in 5 (1.7%), and puncture-site hematoma in 3 (1%). Biochemical toxicities occurred in 57 patients (11.6%). Survival analysis at 12 months showed a progression-free survival rate of 65.9% and overall survival rate of 93.5%. Patients who received transplants showed a 57.7% rate of complete pathologic response. CONCLUSIONS: Chemoembolization with PEG embolic agents for HCC is safe and effective, achieving an objective response rate of 85.5%.
|
Authors | Filipe Veloso Gomes, João A Oliveira, Mariana Tomé Correia, Nuno Vasco Costa, João Abrantes, Daniel Torres, Pedro Pereira, Ana Isabel Ferreira, José Hugo Luz, Erik Spaepen, Tiago Bilhim, Élia Coimbra |
Journal | Journal of vascular and interventional radiology : JVIR
(J Vasc Interv Radiol)
Vol. 29
Issue 6
Pg. 841-849
(06 2018)
ISSN: 1535-7732 [Electronic] United States |
PMID | 29724521
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Contrast Media
- Polyethylene Glycols
|
Topics |
- Aged
- Carcinoma, Hepatocellular
(therapy)
- Chemoembolization, Therapeutic
(methods)
- Contrast Media
- Disease Progression
- Female
- Humans
- Liver Neoplasms
(therapy)
- Male
- Polyethylene Glycols
(administration & dosage)
- Radiography, Interventional
- Retrospective Studies
- Survival Rate
- Tomography, X-Ray Computed
- Treatment Outcome
|